Uncontrolled hypertension is an important clinical problem and is associated with considerable morbidity and mortality. A new report from the SPYRAL HTN-OFF MED researchers, which describes the use of renal denervation in patients with uncontrolled hypertension, might reignite enthusiasm for this technique, while a first-in-human description of endovascular baroreflex amplification from the CALM-FIM_EUR investigators highlights the potential of this new approach to inhibit sympathetic activity.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease study 2016. Lancet 390, 1345–1422 (2017).
de Jager, R. L. et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension 69, 678–684 (2017).
Gupta, P. et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 69, 1113–1120 (2017).
Townsend, R. R. et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32281-X (2017).
Spiering, W. et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32337-1 (2017).
Vink, E. E. et al. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study. Nephrol. Dial Transplant. 29, 1608–1610 (2014).
de Jager, R. L. et al. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin. Res. Cardiol. 105, 755–762 (2016).
Chow, C. K. et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389, 1035–1042 (2017).
de Beus, E. et al. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J. Hypertens. 32, 1751–1761 (2014).
de Jager, R. L. et al. Catheter based renal denervation as therapy for chronic severe kidney related pain. Nephrol. Dial Transplant. http://dx.doi.org/10.1093/ndt/gfx086 (2017).
P.J.B. has received research grants from Medtronic, ZonMw and Nierstichting Nederland. The grants were paid to the institution. M.L.B. declares no competing interests.
About this article
Wearable and Implantable Devices for Cardiovascular Healthcare: from Monitoring to Therapy Based on Flexible and Stretchable Electronics
Advanced Functional Materials (2019)
The Lancet (2018)